Articles
In-depth, research-backed writing on peptides. No hype, no filler — just what the evidence actually says.
Featured
Best Peptides for Recovery: Evidence-Aware Comparison
A cautious comparison of recovery-related peptides by evidence quality, uncertainty, and claim strength — not recommendations, protocols, or buying advice.
Peptides for Recovery: What the Evidence Actually Supports
A pillar guide to peptides for recovery that separates healing, soreness, and injury-repair claims while showing what the evidence actually supports.
All Articles
FDA’s Peptide Compounding Policy Reached White House Review—What That Does (and Does Not) Change
FDA’s peptide compounding policy entered OIRA review in October 2026. Learn what Executive Order 12866 review means—and what it does not change.
AI-Designed Peptides Against Zika: What a 214 µM Lab Hit Really Means
A 2026 study used a recombinant FRET sensor and an AI-assisted design pipeline to find weak micromolar Zika protease inhibitors. Here is what the 214 µM hit proves—and what remains untested.
Personalized Ovarian Cancer Peptide Vaccines: What a 10-Patient Phase 1 Trial Can—and Cannot—Show
A rigorous review of the 10-patient NeoVax ovarian cancer phase 1 trial: cohort feasibility, adverse events, immune and biomarker activity, tumor escape, and why survival benefit remains unproven.
Do GLP-1 Drugs Lower Blood Cancer Risk? Why the Answer Changed With the Comparator
A 2026 matched TriNetX study found no lower hematologic-malignancy incidence versus DPP-4 inhibitors, while three lower-incidence associations appeared versus SGLT2 inhibitors—showing why comparator choice limits causal claims.
Can a Lipidated Peptide Quiet Neuropathic Pain? What the Nav1.8–Ankyrin-3 Mouse Study Shows
A Nav1.8-targeted lipidated peptide reduced neuronal hyperexcitability and pain-like behavior in mice. Here is what the preclinical evidence does—and does not—show.
TR-MOD: What a Biofilm-and-Fibroblast Lab Study Can—and Cannot—Show About a “Wound-Healing” Peptide
TR-MOD inhibited Pseudomonas in broth, interfered with biofilm formation, and increased fibroblast migration in vitro. It did not heal wounds, eradicate mature biofilms, or establish human safety.
GLP-1 Exposure Around Conception: Why “No Detectable Increase” Is Not Proof of Pregnancy Safety
A 2026 meta-analysis found no clearly detectable increase in several pregnancy outcomes after periconceptional GLP-1 exposure, but smaller exposed and outcome-specific samples, heterogeneity, and residual confounding mean the result does not prove safety.
How Might Semaglutide Protect the Kidney? What the REMODEL Trial Found—and Missed
REMODEL's primary kidney MRI outcomes were null, while secondary imaging, albuminuria, kidney-fat and endothelial transcriptomic signals suggested several possible—not proven—mechanisms.
Can a Cyclic Peptide Treat Acne? What the New Lab Study Actually Shows
A 2026 AMCP study found antibacterial, cultured-cell, and ex-vivo skin-permeation signals, plus a five-person uncontrolled product test—not proof of an effective or safe acne treatment.
Can MOTS-c Protect the Diabetic Retina? What the New Cell and Mouse Study Shows
A 2026 study linked MOTS-c to retinal endothelial and mitochondrial protection signals in cultured cells and diabetic mice, with PLA2G6 acting as a model-level mediator—not proof of a human treatment.
NPR3 and Kidney Injury: Why One Mouse Model Looked Protective and Another Did Not
Podocyte-specific Npr3 deletion did not help in DOCA–high-salt hypertension but reduced albuminuria and foot-process effacement after Adriamycin injury in mice.
Retatrutide’s TRIUMPH-2 Trial: Why 20.8% and 18.8% Weight-Loss Headlines Are Both Reported
TRIUMPH-2 reported 20.8% and 18.8% mean weight reduction under different estimands. Learn what each result means, with placebo changes, uncertainty, and safety data.
Do GLP-1 Drugs Cause Nail Detachment? Why the Fourfold Headline Is Not a Causal Verdict
A 2026 EADV survey found much more onycholysis among GLP-1 users, but the new-onset analysis was null. Here is why the fourfold headline does not establish causation.
Can a Self-Assembling Peptide Vaccine Make Cancer Immunotherapy Work Better? What the SaPAC Mouse Study Shows
SaPAC improved delivery, immune activation, and tumor control in mouse experiments, but it has not established human cancer-vaccine efficacy, safety, or personalized-treatment feasibility.
Three Nerve-Injury Cases Do Not Prove BPC-157 or TB-500 Is Effective: How to Read a Multimodal Case Report
What three inferior alveolar nerve injury cases show—and why they do not prove BPC-157, TB-500, ARA-290, or the combination is effective.
Does Semaglutide Raise Pancreatic Cancer Risk? What the Nordic Registry Study Can—and Cannot—Rule Out
A Nordic registry study found no increased pancreatic cancer signal among semaglutide initiators with type 2 diabetes, but short follow-up and conference-only reporting limit what it can rule out.
Can Catestatin Treat Neurodegeneration? What the New Mouse Study Actually Shows
A 2026 study linked catestatin to lower tau, amyloid, and inflammatory readouts in cultures and mouse models—but it did not establish a human treatment.
Does Semaglutide Protect the Heart Beyond Weight Loss? What the SELECT Mediation Analysis Shows
SELECT showed fewer major cardiovascular events with semaglutide. A 2026 mediation analysis found that measured weight and risk-factor changes explained only part of the result, without proving a direct heart mechanism.
Did GLP-1 Drugs Reduce Persistent Opioid Use After Surgery? What 279,250 Matched Pairs Actually Show
A nationwide matched study found fewer later opioid prescription records after surgery among adults with type 2 diabetes exposed to GLP-1 drugs, but its administrative proxy and observational design cannot prove reduced consumption, pain, or addiction.
BPC-157 Use Is Rising—Why 1,039 Clinical Notes Still Do Not Prove It Works
A 2026 preprint found 1,039 documented BPC-157 users and sharply rising use, but incomplete notes, co-treatments and an uncontrolled design cannot prove efficacy or safety.
AI Picked Cobra-Inspired Peptides. Why Did Most Show Little Antibacterial Activity?
Why AI antimicrobial peptide predictions need experimental validation: CTX-p5 showed modest in-vitro activity, not proof of a working antibiotic.
Can Reversing a Peptide Change Its Effects? What a New Cancer-Cell Study Actually Shows
Reversing Trp-X to X-Trp changed cell-growth effects in a modified dipeptide library. Here is what the 48-hour assay shows—and what it cannot prove.
Does a More Stable Peptide Still Work? What the PnPP19 Hydrogel Study Actually Measured
The PnPP19 hydrogel study measured HPLC peptide retention—not biological potency, patient benefit or shelf-life. Here is what its findings can support.
An Immune Response Is Not a Survival Benefit: What Personalized Pancreatic Cancer Vaccines Actually Show
Two small pancreatic cancer vaccine trials showed immune responses—not proven survival benefit. Understand the denominators, assay limits, safety, and registry gaps.
Does Closing a Peptide Into a Ring Make It a Better Drug? What a New Crosslinking Study Shows
Does peptide ring closure make a better drug? Separate stability, integrin binding, cell uptake and cell-growth evidence from clinical proof.
Did the Peptide Cause the Effect? What a TFA Counterion Study Reveals
A TFA counterion study shows why peptide preparation effects need careful controls—and why mouse lipid findings do not establish human benefit.
Can AI Design Mirror-Image Peptides? What Mirror-Peptidizer Actually Proved
An evidence-aware guide to AI-designed D-peptides, the Mirror-Peptidizer workflow, its MDM2, PD-L1, and IL-23R experiments, and the limits of the proof.
Did Semaglutide Extend Lifespan? What the Female-Mouse Ageing Study Actually Shows
A 2026 Nature study found longer median lifespan in older female mice given semaglutide, but separate cohorts, reduced food intake and animal-only evidence sharply limit the human claim.
Why ‘Not Found in Healthy Tissue’ Does Not Prove a Peptide Cancer Target Is Safe
A plain-English guide to peptide-HLA cancer targets, normal-tissue immunopeptidome evidence, and why a missing database hit is not proof of safety.
FDA Warned Four Peptide Sellers at Once: What the September 2026 Letters Actually Say
FDA's four September 2026 peptide seller warning letters show why research-only disclaimers did not outweigh human-drug claims, bacteriostatic water, guides, calculators, and other injection-related sales context.
Can Ancient Lactoferrin Peptides Kill Drug-Resistant Bacteria? What the Resurrection Study Actually Shows
A 2026 PLOS Biology study reconstructed ancestral lactoferricin peptides and found evolving membrane disruption and bactericidal activity in laboratory strains—but no therapeutic proof.
Compounded Glutathione Recalls: What Endotoxin Contamination Actually Means
The 2026 compounded glutathione recalls concern elevated bacterial endotoxin in specific injectable lots—not proof that glutathione itself caused the reported events.
Do GLP-1 Drugs Lower Tuberculosis Risk? What the New Observational Study Can—and Cannot—Show
A large matched observational study linked GLP-1 receptor agonist use with lower recorded tuberculosis incidence, but it cannot establish prevention or guide drug choice.
Can Cyclic Peptides Tune TREM2? What the New Microglia Study Actually Shows
A 2026 study found micromolar TREM2-binding cyclic peptides that altered amyloid-stressed microglial cell models—but did not test brain exposure, animal efficacy, or Alzheimer’s benefit.
Is MOTS-c a Host-Defense Peptide? What the New MRSA Study Actually Shows
A 2026 eLife paper supports MOTS-c as a mitochondrial host-defense peptide in bacterial, cell, and mouse experiments—but it did not test MOTS-c as an infection treatment in people.
Can a Frog Peptide Heal Skin Wounds? What the OL-RA11 Autophagy Study Actually Shows
A 2026 study linked OL-RA11 to macrophage autophagy, keratinocyte Wnt signaling, and faster wound repair in mice. The mechanism is coherent, but human efficacy and safety remain unknown.
GLP-1 Drugs and Gastroparesis: What 13 Published Cases Can—and Cannot—Show
A 2026 systematic review found only 12 case reports describing 13 patients. Here is what that GLP-1 gastroparesis evidence signals—and why it cannot establish incidence, causality, or comparative drug risk.
Can Bacteria Resist Programmable Antisense Antibiotics? Why the Delivery Peptide Matters
Can bacteria resist programmable antisense antibiotics? Learn how PNA target mutations and peptide-dependent uptake resistance differ—and why laboratory evolution is not clinical proof.
Can a Self-Assembling Peptide Repair Tendons? What the Rat and Beagle Study Actually Shows
A 2026 study linked an engineered TGF-β1-capturing peptide to tendon repair measures in rats and beagles. Here is what the preclinical evidence does—and does not—show.
Do GLP-1 Drugs Increase Bowel Obstruction Risk? What a 298,124-Person Study Found
A nationwide Japanese study found no increased one-year risk of serious bowel obstruction or ileus after GLP-1 receptor-agonist initiation versus SGLT2-inhibitor initiation, but important limits remain.
OPT101 for Type 1 Diabetes: What the Small Phase 1b Trial Actually Shows
What the randomized OPT101 phase 1b type 1 diabetes trial shows about short-term tolerability, Th40 biomarkers, HbA1c and C-peptide—and what remains unproven.
One Patient, 26 Months: What an EWSR1–FLI1 Peptide Vaccine Case Report Actually Shows
What one EWSR1–FLI1 peptide vaccine case report shows about immune response and disease stability—and why it cannot prove treatment benefit.
GLP-1 Weight Loss and AgRP Neurons: What the New Female-Mouse Study Actually Shows
A 2026 PNAS study found that intact AgRP neuron circuitry was needed for the full weight-lowering response to GLP-1 receptor agonists in female mice. Here is what that causal result means—and what it cannot establish in humans.
Pegtarazimod for Steroid-Refractory GVHD: What 7 Patients and Mouse Studies Actually Show
A plain-English evidence review of pegtarazimod for acute graft-versus-host disease, separating mouse, organoid, and seven-patient findings.
Survodutide and MASH: How Much Liver Improvement Was Explained by Weight Loss?
A careful evidence-literacy guide to the 2026 survodutide MASH mediation analysis—and why weight-loss-independent does not prove a receptor-specific liver effect.
TE-8105: What a 38-Person First-in-Human Long-Acting GLP-1 Trial Actually Shows
TE-8105 had an approximately 120-hour half-life in a 38-person open-label Phase 1 study. Here is what that finding—and the early weight and safety observations—can and cannot establish.
Can Adults Safely Use Grey-Market Semaglutide? What a 20-Person Simulation Actually Shows
What a 20-person simulation reveals about grey market semaglutide safety, self-injection process errors, confidence, product uncertainty, and study limitations.
Can an Oral Cyclic Peptide Block RAS? What LUNA18 (Paluratide) Actually Shows
What LUNA18 paluratide shows about oral cyclic-peptide pan-RAS inhibition—and why its preclinical results do not prove patient benefit.
Can a Nanopore Read a Peptide One Amino Acid at a Time? What the New Nature Study Shows
A 2026 Nature study used an engineered nanopore to reread an immobilized peptide as an enzyme shortened it one residue at a time. Here is what tPAL proved—and what it did not.
What Health Canada’s Canlab Peptide Injunction Actually Means
What Health Canada’s permanent Canlab injunction prohibits, how it followed earlier warnings and a Ministerial Order, and why it is not a ban on every peptide medicine.
How Tissue-Damage Peptides May Block Lung Repair: What the New COPD Study Shows
A 2026 COPD study links elastin-derived peptides to impaired alveolar repair across human tissue, organoids, and mice—but the intervention evidence remains preclinical.
FDA Panel Backed Six Peptides for Compounding—What the Vote Does (and Does Not) Mean
The FDA advisory panel backed 503A Bulks List inclusion for the free-base and acetate forms of six peptide groups and rejected emideltide/DSIP. Here is what the non-binding vote means—and what it does not prove.
GIP Agonism vs Antagonism: Why Opposite Strategies Can Both Reduce Food Intake in Mice
A 2026 mouse study suggests GIPR agonism and antagonism can affect food intake and body weight through distinct brain regions—not interchangeable mechanisms.
Can a Peptide Vaccine Target IL-17A? What a 20-Person Phase 1 Trial Does—and Does Not—Show
What the 20-person FPP003 phase 1 trial shows about IL-17A peptide-vaccine safety and antibody responses—and why it does not prove neutralization or disease benefit.
Do GLP-1 Drugs Cause Hair Loss? What the New BMJ Study Actually Shows
A 2026 BMJ target-trial emulation found a low-frequency association between GLP-1 receptor agonists and non-scarring alopecia in adults with type 2 diabetes, but it did not prove causation.
When a Peptide Cancer Study Is Retracted: What Retraction Does—and Does Not—Mean
What a peptide study retraction means, why ethics and provenance concerns can undermine confidence, and how readers can verify a paper's current status.
Peptides for Long COVID: What Is Being Studied—and What Is Only Being Marketed
No peptide is proven to treat Long COVID. Separate controlled trials of tirzepatide and larazotide from planned research, animal studies, anecdotes, and marketing.
Can a Peptide Vaccine Lower Cholesterol? What the PCSK9 Animal Study Actually Shows
A plain-English review of the 2026 PCSK9 peptide vaccine animal study, including its design, findings, limitations, and differences from PCSK9 antibodies and oral inhibitors.
Can a KRAS Peptide Vaccine Prevent Pancreatic Cancer? What the First Human Trial Actually Shows
The first human mKRAS-VAX study generated mutant-KRAS-specific T-cell responses in 18 of 20 high-risk participants—but it did not prove pancreatic cancer prevention.
Can AI Predict a Good Peptide Drug? What PeptiVerse Can—and Cannot—Prove
An evidence-aware guide to PeptiVerse, AI peptide property prediction, dataset limits, applicability domain, uncertainty, and why computational prioritization is not drug proof.
GLP-1 Drugs and Rare Optic-Nerve Risk: What the New NAION Studies Actually Show
Two large observational studies found a small association between GLP-1 receptor agonists and ischemic optic neuropathy, but the absolute event rate was very low and causation remains uncertain.
Setmelanotide and Hypothalamic Obesity: What the Phase 3 Trial Actually Shows
The phase 3 TRANSCEND trial found large BMI and hunger reductions with setmelanotide in acquired hypothalamic obesity, alongside a substantial adverse-event burden.
Afamelanotide and EPP: What Canada’s SCENESSE Approval Shows About Real Peptide Medicine
What afamelanotide SCENESSE does for adults with EPP, what the trials and labels show, and why regulated peptide medicine differs from tanning or research-peptide marketing.
Could Astronauts Make Peptide Medicines in Space? What the New Astropharmacy Study Actually Shows
A 2026 study ranked 26 peptide medicines for possible on-demand spaceflight production. Here is what the scoring shows—and what it does not prove.
AI Peptide Design: Why Binding Is Not the Same as Biological Effect
AI can predict that a peptide may bind a receptor, but binding alone does not reveal whether it activates, blocks, or meaningfully changes that receptor. TD3B shows why directionality matters—and why computational candidates still require laboratory and clinical validation.
Why Peptide Manufacturing Quality Is Hard: The EMA Synthetic-Peptide Guideline, Translated
A plain-English guide to synthetic peptide manufacturing quality, based on the EMA guideline effective June 1, 2026.
PepCan and HPV Peptide Vaccines: How to Read Early Cancer Vaccine Trials
The small PepCan trial did not prove that an HPV peptide vaccine prevents cancer recurrence. It shows why safety, immune signals, efficacy, statistical power, production problems, and conflicts must be read separately.
Peptides in Real Medicine: PRRT, Edotreotide, and Neuroendocrine Tumor Evidence
What the phase 3 COMPETE trial of [177Lu]Lu-edotreotide versus everolimus teaches about peptide receptor radionuclide therapy, disease-specific evidence, and why regulated peptide medicines should not be confused with wellness peptide marketing.
FDA Research Peptide Compounding Review: What It Is and What It Is Not
A cautious explainer on FDA's July 2026 review of seven peptide-related bulk drug substances for the 503A Bulks List, why staff opposition matters, and why the review is not FDA approval or proof of safety.
When a Peptide Enters Phase 1: What That Actually Means
Recent KIT2014 and Nubytide/8M2D peptide trial updates are useful examples of how to read early clinical-development news: meaningful, but not proof that a peptide works, is approved, or belongs in wellness marketing.
GLP-1 Side Effects: What Trials, Labels, and Online Communities Can Each Tell Us
GLP-1 side-effect claims mean different things depending on whether they come from clinical trials, FDA labels, adverse-event databases, or online communities. This evidence-method guide explains how to read each source without turning anecdotes into proof or labels into panic.
Research Use Only Peptides: What That Label Does and Does Not Mean
A cautious explainer on research use only peptides, what RUO labeling is meant to signal, and why it does not prove safety, legality, sterility, or suitability for human use.
Is Orforglipron a Peptide? The New Oral GLP-1 Pill Explained
Orforglipron is an oral, non-peptide small-molecule GLP-1 receptor agonist. This clarifier explains why people confuse it with peptide GLP-1 drugs and how FDA-approved Foundayo differs from research peptides.
CagriSema Explained: Semaglutide, Cagrilintide, and the Amylin + GLP-1 Strategy
A cautious, evidence-aware explainer on CagriSema, the investigational semaglutide plus cagrilintide combination, and why the amylin + GLP-1 strategy is not just stronger semaglutide.
What Is Epitalon? Longevity Claims, Telomeres, and the Evidence Gap
Epitalon is searched as a telomere and longevity peptide, but the evidence is strongest for cell and animal biology and much weaker for proven human anti-aging outcomes.
What Is Tesamorelin? Visceral Fat Claims, Growth-Hormone Pathways, and Evidence
Evidence-aware explanation of tesamorelin, why it is searched around visceral fat and body composition, what the HIV-associated VAT evidence supports, how GH/IGF-1 pathway claims are often generalized, and where side-effect boundaries matter.
GLP-1 Peptides vs “Research Peptides”: What People Mean and Why It Matters
A clear, evidence-aware guide to why GLP-1 drugs are peptides, how semaglutide and tirzepatide differ from vague research-peptide marketing, and why regulatory status matters.
What Is MOTS-c? The Mitochondrial Peptide People Are Searching For
MOTS-c is a mitochondrial-derived peptide studied for metabolic and stress-response signaling, but longevity, fat-loss, and energy claims remain much less certain than the online hype suggests.
Sermorelin vs Ipamorelin: What’s the Difference?
Sermorelin and ipamorelin are both discussed as growth-hormone-secretagogue-related peptides, but they differ by pathway, evidence base, and safety uncertainty.
What Is CJC-1295? DAC vs No-DAC, Ipamorelin Combinations, and Evidence
Evidence-aware explanation of CJC-1295, DAC vs no-DAC terminology, why it is searched with ipamorelin, what human marker evidence can and cannot show, and where side-effect uncertainty remains.
Peptide Therapy Explained: What Clinics Mean, What’s Evidence-Based, and What’s Marketing
A cautious, evidence-aware guide to what peptide therapy means in clinics and marketing, how approved medicines differ from research compounds, and what questions to ask before trusting a claim.
BPC-157 and TB-500 Together: Evidence, Claims, and What’s Still Speculative
An evidence-aware guide to why BPC-157 and TB-500 are often discussed together, what mechanisms are claimed, what evidence exists separately versus as a combination, and where online recovery claims outrun the data.
What Is GHK-Cu? Copper Peptide Benefits, Skin Claims, Hair Growth, and Evidence
GHK-Cu is a copper-binding tripeptide with real skin and wound-biology research, plausible topical cosmetic relevance, weaker hair-growth certainty, and many consumer claims that run ahead of the evidence.
Peptide Side Effects: What's Known, What's Unknown, and What People Overstate
A cautious, evidence-aware guide to peptide side effects, long-term unknowns, online claims, and how to read safety discussions without mistaking anecdotes for proof.
How to Evaluate Peptide Claims Online
A practical framework for reading peptide claims online: how to separate human evidence from preclinical signals, spot hype, and avoid mistaking confident marketing for proof.
TB-500 Side Effects and Unknowns: What Safety Evidence Actually Shows
TB-500 is often discussed as a recovery peptide, but its human safety profile is still uncertain. Here is what is known, what is not known, and how to read side-effect claims carefully.
BPC-157 Side Effects and Unknowns: What Safety Evidence Actually Says
BPC-157 is often described as well tolerated, but human safety evidence is still thin. Here are the known side effects, theoretical risks, and biggest unknowns.
What Is BPC-157? Benefits, Evidence, Risks, and What We Actually Know
BPC-157 is a synthetic peptide often discussed for tissue repair, gut protection, and injury recovery, but most evidence is still preclinical.
What Is TB-500? An Evidence-Aware Overview
An evidence-aware overview of TB-500, its relationship to thymosin beta-4, what it is commonly discussed for, and where the evidence remains limited.
What Preclinical Actually Means in Peptide Research
A practical explainer on what preclinical actually means in peptide research, why it matters, and how to read early-stage evidence without inflating certainty.
BPC-157 vs TB-500: What's the Difference, and Which Recovery Peptide Question Are You Actually Asking?
BPC-157 and TB-500 are often discussed together for healing and recovery, but they have different mechanism stories, different common use cases, and similarly limited human evidence.
Peptide Research Status Explained: How to Judge the Evidence Before You Read Any Compound Page
Learn how to interpret peptide research stages so you can tell the difference between mechanistic theory, animal data, early human studies, and evidence that actually deserves confidence.